Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
Kunz P, de Bruin M, Balise R, Fisher G, Ford J. Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15686-e15686. DOI: 10.1200/jco.2009.27.15_suppl.e15686.Peer-Reviewed Original ResearchStanford Cancer CenterGastroesophageal junction cancerMetastatic gastricJunction cancerRetrospective reviewPossible treatment-related deathSingle-institution retrospective reviewCarboplatin AUC 6Regimen of carboplatinCycles of chemotherapyMedian overall survivalTreatment-related deathsStandard chemotherapy regimenFourty-five patientsGastroesophageal junction adenocarcinomaFluoropyrimidine-based treatmentSignet ring featuresAUC 6Chemotherapy-naïvePo bidChemotherapy regimenOnly patientsOverall survivalJunction adenocarcinomaMedian age